Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
Ikena, Senti and others look to clinical presentations at AACR.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
